China Medical System Holdings Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Kong Lam

Geschäftsführender

CN¥5.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	93.5%
Amtszeit als Geschäftsführer	18yrs
Eigentum des Geschäftsführers	48.3%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	12.5yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Kong Lam im Vergleich zu den Einnahmen von China Medical System Holdings verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	CN¥1b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥5m	CN¥5m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥3b
Jun 30 2023	n/a	n/a	CN¥3b
Mar 31 2023	n/a	n/a	CN¥3b
Dec 31 2022	CN¥6m	CN¥5m	CN¥3b
Sep 30 2022	n/a	n/a	CN¥3b
Jun 30 2022	n/a	n/a	CN¥3b
Mar 31 2022	n/a	n/a	CN¥3b
Dec 31 2021	CN¥5m	CN¥4m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥3b
Dec 31 2020	CN¥4m	CN¥4m	CN¥3b
Sep 30 2020	n/a	n/a	CN¥2b
Jun 30 2020	n/a	n/a	CN¥2b
Mar 31 2020	n/a	n/a	CN¥2b
Dec 31 2019	CN¥4m	CN¥3m	CN¥2b
Sep 30 2019	n/a	n/a	CN¥2b
Jun 30 2019	n/a	n/a	CN¥2b
Mar 31 2019	n/a	n/a	CN¥2b
Dec 31 2018	CN¥3m	CN¥3m	CN¥2b
Sep 30 2018	n/a	n/a	CN¥2b
Jun 30 2018	n/a	n/a	CN¥2b
Mar 31 2018	n/a	n/a	CN¥2b
Dec 31 2017	CN¥782k	CN¥610k	CN¥2b

Vergütung im Vergleich zum Markt: KongDie Gesamtvergütung ($USD745.70K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD511.75K).

Entschädigung vs. Einkommen: KongDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Kong Lam (59 yo)

18yrs

Amtszeit

CN¥5,443,000

Vergütung

Dr. Lam Kong founded and serves as the Chairman and Chief Executive Officer of China Medical System Holdings Limited and has been its Executive Director since December 18, 2006. Mr. Lam serves as President...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kong Lam	Founder	18yrs	CN¥5.44m	48.32% HK$ 8.8b
Yanling Chen	CFO, VP & Executive Director	18yrs	CN¥4.43m	0.30% HK$ 54.5m
Chong Shun Leung	Independent Non-Executive Director	7yrs	CN¥323.00k	keine Daten
Hongbing Chen	Non-Executive Director	18yrs	CN¥5.04m	2.91% HK$ 528.4m
Ying Luo	Independent Non-Executive Director	4.8yrs	CN¥323.00k	keine Daten
Ching Fung	Independent Non-Executive Director	3.2yrs	CN¥323.00k	keine Daten

12.5yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrener Vorstand: 867Die Vorstandsmitglieder sind sehr erfahren ( 12.5 ).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2024/12/27 02:34
Aktienkurs zum Tagesende	2024/12/27 00:00
Gewinne	2024/06/30
Jährliche Einnahmen	2023/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

^* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .

Analysten-Quellen

China Medical System Holdings Limited wird von 34 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Jessica Li	BofA Global Research
Lok Kwan Chiu	CCB International Securities Limited
Harry He	China Galaxy International Securities (Hong Kong)

China Medical System Holdings Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Insufficient new directors

Founder recently bought HK$3.6m worth of stock

China Medical System Holdings Limited Announces Re-Designation of Directors

Founder recently bought HK$6.8m worth of stock

China Medical System Holdings Limited, Annual General Meeting, May 09, 2024

Founder recently bought HK$23m worth of stock

Recent updates

China Medical System Holdings Limited Announces First Prescription for Innovative Drug Lumeblue Issued in China

China Medical System Holdings Limited Announces Approval of Drug Clinical Trials for Innovative Drug

China Medical System Holdings Limited Announces New Drug Application of Ruxolitinib Phosphate Cream for Vitiligo Approved in Hong Kong

Insufficient new directors

Investor sentiment improves as stock rises 20%

China Medical System Holdings Limited Announces New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China

Founder recently bought HK$3.6m worth of stock

First half dividend of HK$0.16 announced

First half 2024 earnings released: EPS: CN¥0.37 (vs CN¥0.78 in 1H 2023)

China Medical System Holdings Limited Announces Re-Designation of Directors

China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on About 9 September 2024

China Medical System Holdings Limited Announces NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China

China Medical System Holdings Limited to Report First Half, 2024 Results on Aug 15, 2024

China Medical System Holdings Limited Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China

China Medical System Holdings Limited Announces Approval of Lumeblue® by NMPA for Enhanced Colorectal Lesion Detection

Now 20% undervalued after recent price drop

Founder recently bought HK$6.8m worth of stock

Now 20% undervalued after recent price drop

China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023

Now 21% undervalued after recent price drop

China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 40%

China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024

Final dividend of HK$0.086 announced

China Medical System Holdings Limited, Annual General Meeting, May 09, 2024

Now 38% undervalued after recent price drop

Full year 2023 earnings released: EPS: CN¥0.98 (vs CN¥1.33 in FY 2022)

China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024

China Medical System Holdings Limited Announces Approval to Conduct A Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China

China Medical System Holdings Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

China Medical System Holdings Limited Announces Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Vitiligo in China

China Medical System Holdings Limited Announces That on 4 December 2023, the New Drug Application (Nda) for an Additional Indication of Methotrexate Injection Has Been Accepted by the National Medical Products Administration of China

Upcoming dividend of HK$0.34 per share at 5.1% yield

First half 2023 earnings released: EPS: CN¥0.78 (vs CN¥0.73 in 1H 2022)

China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 20, 2023

China Medical System Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023

China Medical System Holdings Limited Receives Approval from National Medical Products Administration of China for New Drug Application of Diazepam Nasal Spray

National Medical Products Administration of China Approves China Medical System Holdings's New Drug Application of Tildrakizumab Injection under the Brand Name of ILUMETRI

Upcoming dividend of HK$0.27 per share at 4.5% yield

Full year 2022 earnings released: EPS: CN¥1.33 (vs CN¥1.22 in FY 2021)

China Medical System Holdings Limited Announces New Drug Application of Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets

China Medical System Holdings Limited Announces its Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets Obtains Positive Results for its Phase III Clinical Trial in China

Investor sentiment improved over the past week

Upcoming dividend of HK$0.34 per share

First half 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.66 in 1H 2021)

China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 15 September 2022

China Medical System Holdings Limited to Report First Half, 2022 Results on Aug 22, 2022

China Medical System Holdings Limited Approves Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.28 per share

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

China Medical System Holdings Limited to Report Fiscal Year 2021 Results on Mar 15, 2022

China Medical System Holdings Limited Announces New Drug Application of Methotrexate Injection, Pre-Filled Syringe Accepted in China

Independent Non-Executive Director Chi Keung Wu has left the company

China Medical System Holdings Limited Establishes A New Programme with XF-73 Targeting the Prevention and Treatment of Superficial Skin Infections Caused by Bacteria

Upcoming dividend of HK$0.32 per share

First half 2021 earnings released: EPS CN¥0.66 (vs CN¥0.52 in 1H 2020)

National Medical Products Grants Approval to China Medical System Holdings Limited's Methotrexate Injection, Pre-Filled Syringe

China Medical System Holdings Limited Receives Approval for Innovative Patented Drug Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets

China Medical System Holdings Limited Announces That the Group's Innovative Drug Tildrakizumab Solution for Injection Obtained Positive Results of Its Phase Clinical Trial in China

China Medical System Holdings Limited Announces New Drug Application of Diazepam Nasal Spray Accepted in China

China Medical System Holdings Limited Approves Final Dividend for the Year Ended December 31, 2020

Upcoming dividend of HK$0.24 per share

Full year 2020 earnings released: EPS CN¥1.02 (vs CN¥0.79 in FY 2019)

China Medical System Holdings Limited Recommends a Final Dividend for the Year Ended 31 December 2020, Payable About 10 May 2021

Full year 2020 earnings released

Investor sentiment improved over the past week

China Medical System Holdings Limited to Report Fiscal Year 2020 Results on Mar 16, 2021